UnknownPhase 2NCT04797182

Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma

Studying Immune thrombocytopenia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sun Yat-sen University
Principal Investigator
Qingqing Cai, MD
Sun Yat-sen University
Intervention
avatrombopag(drug)
Enrollment
46 target
Eligibility
18-70 years · All sexes
Timeline
2021 – 2023

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04797182 on ClinicalTrials.gov

Other trials for Immune thrombocytopenia

Additional recruiting or active studies for the same condition.

See all trials for Immune thrombocytopenia →

← Back to all trials